Raspa M, Sacco P, Candrilli SD, Bishop E, Petrillo J. Validity of a condition specific outcome measure for fragile X syndrome: the Aberrant Behaviour Checklist-utility index. J Intellect Disabil Res. 2016 Sep;60(9):844-55. doi: 10.1111/jir.12264
Graham J, Earnshaw S, Lim J, Luthra R, Borker R. Cost-effectiveness of afatinib versus erlotinib in the first-line treatment of patients with metastatic non-small cell lung cancer with EGFR Exon 19 deletion mutations. JCP. 2016 May;2(4):31-9.
Carney RSE, Cocas LA, Hirata T, Mansfield K, Corbin JG. Differential regulation of telencephalic pallial-subpallial boundary patterning by Pax6 and Gsh2. Cereb Cortex. 2009 Apr;19(4):745-59. doi: 10.1093/cercor/bhn123